IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

PASSAMONTI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 14.136
AS - Asia 11.659
NA - Nord America 8.618
SA - Sud America 1.319
AF - Africa 308
OC - Oceania 264
Continente sconosciuto - Info sul continente non disponibili 6
Totale 36.310
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.097
DE - Germania 5.822
CN - Cina 3.655
SG - Singapore 3.074
IT - Italia 2.967
GB - Regno Unito 1.077
BR - Brasile 961
HK - Hong Kong 901
VN - Vietnam 755
RU - Federazione Russa 732
BD - Bangladesh 720
FR - Francia 710
IN - India 691
JP - Giappone 570
ES - Italia 513
FI - Finlandia 382
NL - Olanda 324
CA - Canada 304
ID - Indonesia 268
AU - Australia 240
SE - Svezia 220
CH - Svizzera 211
KR - Corea 211
PL - Polonia 203
IE - Irlanda 182
TR - Turchia 182
AT - Austria 152
MX - Messico 139
AR - Argentina 129
GR - Grecia 104
BE - Belgio 92
TW - Taiwan 80
EG - Egitto 75
CO - Colombia 71
CZ - Repubblica Ceca 67
PK - Pakistan 61
IQ - Iraq 59
TH - Thailandia 58
CI - Costa d'Avorio 56
SA - Arabia Saudita 54
DK - Danimarca 51
IL - Israele 47
PT - Portogallo 47
ZA - Sudafrica 46
IR - Iran 38
EC - Ecuador 37
JO - Giordania 35
MA - Marocco 35
PH - Filippine 35
HU - Ungheria 34
PE - Perù 34
RO - Romania 34
MY - Malesia 33
UA - Ucraina 33
CL - Cile 25
LT - Lituania 24
NZ - Nuova Zelanda 24
TN - Tunisia 23
NP - Nepal 20
SI - Slovenia 20
VE - Venezuela 20
KE - Kenya 18
CR - Costa Rica 17
NO - Norvegia 17
PY - Paraguay 17
NG - Nigeria 16
UY - Uruguay 16
BA - Bosnia-Erzegovina 15
HR - Croazia 15
UZ - Uzbekistan 15
BY - Bielorussia 14
MD - Moldavia 14
KZ - Kazakistan 13
AE - Emirati Arabi Uniti 9
AL - Albania 9
GT - Guatemala 9
HN - Honduras 9
JM - Giamaica 9
OM - Oman 9
RS - Serbia 9
EE - Estonia 8
EU - Europa 8
MM - Myanmar 8
BG - Bulgaria 7
LU - Lussemburgo 7
QA - Qatar 7
AZ - Azerbaigian 6
CY - Cipro 6
LV - Lettonia 6
MK - Macedonia 6
ET - Etiopia 5
GY - Guiana 5
KW - Kuwait 5
LB - Libano 5
LY - Libia 5
SC - Seychelles 5
SV - El Salvador 5
SY - Repubblica araba siriana 5
AP - ???statistics.table.value.countryCode.AP??? 4
BH - Bahrain 4
Totale 36.231
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 5.131
Singapore 1.350
Ashburn 921
Hefei 744
Hong Kong 704
Milan 677
San Jose 584
Dallas 581
Santa Clara 452
Council Bluffs 383
Southend 378
Beijing 338
Helsinki 308
Los Angeles 308
Bengaluru 283
New York 268
Rome 240
Ho Chi Minh City 239
Tokyo 216
Hanoi 203
Seattle 189
Lauterbourg 184
Dublin 180
Fairfield 179
Jakarta 174
Moscow 174
Guangzhou 169
Buffalo 166
Shanghai 153
Florence 144
Chicago 131
Madrid 129
São Paulo 123
Wilmington 117
Chandler 116
Tianjin 109
Houston 105
Paris 105
Barcelona 103
Seoul 103
Princeton 102
London 101
Vienna 96
Cambridge 91
Bologna 88
Naples 78
Woodbridge 77
Boston 75
Nuremberg 75
Hangzhou 74
Nanjing 74
Redwood City 72
Istanbul 65
Amsterdam 64
Atlanta 64
Hyderabad 63
Munich 63
Zurich 61
Genoa 60
Toronto 60
Warsaw 59
Melbourne 58
Shenzhen 58
Abidjan 56
Mumbai 56
Washington 56
Sydney 54
Cangzhou 53
Ann Arbor 52
Reston 51
Boardman 50
Brisbane 50
Manchester 50
Columbus 47
Des Moines 45
Gurugram 43
Montreal 43
Taipei 42
Chengdu 40
Rochester 40
Bangkok 39
Rio de Janeiro 39
Alexandria 38
Bogotá 38
Lappeenranta 38
Turin 38
Ankara 37
Berlin 37
Brooklyn 36
Buenos Aires 36
Da Nang 35
Palermo 35
Philadelphia 35
Phoenix 35
Salt Lake City 35
Athens 34
Hamburg 34
The Dalles 34
Wuhan 33
Zhengzhou 32
Totale 20.385
Salva come PNG Salva come JPEG
Nome #
MIPSS70 : Mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis 2.963
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 2.121
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes 904
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia 882
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group 634
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study 564
Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis 499
Polycythemia vera: From new, modified diagnostic criteria to new therapeutic approaches 450
Associations between gender, disease features and symptom burden in the MPN population : An analysis by the MPN QOL International Working Group 433
Aberrant single-cell phenotype and clinical implications of genotypically defined polyclonal plasma cells in myeloma 409
Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT 358
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project 323
The European Hematology Association Roadmap for European Hematology Research: a consensus document 318
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) 314
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 300
Stereotyped patterns of B-CELL receptor in splenic marginal zone lymphoma 299
COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA) 259
In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent 255
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia 255
Glycolytic activity and in vitro effect of the pyruvate kinase activator AG‐946 in red blood cells from low‐risk myelodysplastic syndromes patients: A proof‐of‐concept study 251
Transfusions in autoimmune hemolytic anemias: Frequency and clinical significance of alloimmunization 247
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy 246
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 244
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations 242
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 233
The pleiotropic nature of NONO, a master regulator of essential biological pathways in cancers 227
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 227
Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review 225
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis : a study on 2233 patients 225
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 225
Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet 217
Bortezomib-based therapy in non-transplant multiple myeloma patients: a retrospective cohort study from the FABIO project 212
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV 211
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients 211
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies : results from EPICOVIDEHA survey 208
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years [Clinical relevance of clonal hematopoiesis in persons aged >= 80 years] 207
The role of jak2 inhibitors in mpns 7 years after approval 206
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 206
Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders : a phase 2 multicenter study 206
European Bone Marrow working group trial on reproducibility of World health organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5 - Comment 204
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts 204
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms 199
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study 198
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score 197
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study 196
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis 191
Targeting exhausted cytotoxic T cells through CTLA‐4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts 187
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 185
Circulating biomarkers in familial cerebral cavernous malformation 185
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial 182
Investigation of the biological and molecular relevance of NONO protein in multiple myeloma 181
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes 181
Primary nodal marginal zone B-cell lymphoma : clinical features and prognostic assessment of a rare disease 181
Inference of genomic lesions from single-cell RNA-seq in myeloma improves functional intraclonal and interclonal analysis 180
Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data 179
Second primary malignancies in ruxolitinib-treated myelofibrosis : real-world evidence from 219 consecutive patients 176
Stem cell transplant in MF: It’s time to personalize 167
FUNCTIONAL DISSECTION OF THE SINGLE CELL TRANSCRIPTOMIC LANDSCAPE OF GENOTYPICALLY-IDENTIFIED POLYCLONAL PLASMACELLS IN MULTIPLE MYELOMA MICROENVIRONMENT 167
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project 166
Stereotyped patterns of HCDR3 sequences in splenic marginal zone B-Cell lymphoma (SMZL) : SMZL-biased subsets are associated with a worse outcome 162
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study 159
Immunomodulatory cytokines and clonal dynamics in low‐risk myelodysplastic syndromes patients treated with luspatercept 159
Defining disease modification in myelofibrosis in the era of targeted therapy 158
EPICOVIDEHA: A ready to use platform for epidemiological studies in hematological patients with COVID-19 158
Exploring the role of NONO in transcriptional regulation of cellular pathways in Multiple Myeloma: insights into its paraspeckle-dependent and independent regulatory mechanisms 158
COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP 157
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis 155
In silico-identified putative inhibitors of paraspeckle assembly induce cell death by apoptosis in Multiple Myeloma cells and lead to the activation of the cGAS/STING pathway. 154
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study 152
Natural history of chronic idiopathic neutropenia of the adult 152
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure 152
INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia 151
The biological relevance of upregulated NONO protein in multiple myeloma through the regulation of cell cycle progression and drug treatment response 150
Value and limitations of targeted next-generation sequencing in idiopathic hypereosinophilia: an integrative diagnostic tool in challenging cases 149
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes 146
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial 145
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group 145
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis : A study on 359 patients of the AGIMM group 145
COVID-19 in vaccinated adult patients with hematological malignancies : Preliminary results from EPICOVIDEHA 145
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA interdisciplinary expert consensus 143
The EHA research roadmap: malignant myeloid diseases 142
Myelofibrosis 142
MYSEC-Prognostic Model and previous thrombotic events predict the risk of thrombosis in post polycythemia vera and post essential thrombocythemia myelofibrosis: a study of the MYSEC Group 142
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts 141
Early treatment for COVID-19 in patients with haematological malignancies: Much more than a recommendation! 141
A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good! 141
Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies 140
Efficacy and safety of low-dose aspirin in polycythemia vera 139
NONO is required for multiple myeloma cell lines growth through stabilisation of lncRNA NEAT1 and paraspeckle integrity 138
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses 138
Update from the latest WHO classification of MPNs: a user's manual 137
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study 137
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations 136
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): A randomised, open-label, phase 3 trial 135
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia 135
Deciphering molecular complexity of HCV-associated lymphoproliferation 135
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study) 135
Germline RBBP6 mutations in familial myeloproliferative neoplasms 134
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis : a consensus process by an EBMT/ELN international working group 134
Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection 133
Totale 26.672
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.915
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.915
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.110 133 130 124 166 151 139 189 288 275 166 122 227
2022/20231.975 163 129 122 150 152 207 139 167 252 144 202 148
2023/20246.352 140 151 449 202 422 308 896 802 422 758 885 917
2024/20257.460 763 775 649 621 354 349 474 502 425 600 602 1.346
2025/202617.198 1.438 1.767 2.148 1.520 1.135 988 1.547 918 1.557 1.007 1.507 1.666
2026/2027170 170 0 0 0 0 0 0 0 0 0 0 0
Totale 37.408